Results 51 to 60 of about 9,857 (174)
An immunosuppressed 40‐year‐old man developed rapidly progressive polymicrobial pneumonia caused by Pneumocystis jirovecii and carbapenem‐resistant Klebsiella pneumoniae. Three metagenomic next‐generation sequencing (mNGS) and targeted next‐generation sequencing (tNGS) workflows with different assay designs and technical parameters consistently ...
Mengxia Wang, Jielun Wen, Liyue Sun
wiley +1 more source
Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber +2 more
doaj +1 more source
As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi +8 more
doaj +1 more source
Global dissemination of tmexCD‐toprJ across bacterial hosts and ecological niches is accompanied by its convergence with blaKPC, blaNDM, and mcr on mobile plasmids. Recombination and acquisition of resistance modules generate distinct multidrug resistant plasmid architectures, facilitating the emergence and spread of high‐risk bacterial populations ...
Kaiwen Song +9 more
wiley +1 more source
ABSTRACT Two neonates with metallo‐β‐lactamase‐producing Acinetobacter baumannii meningitis, resistant to every tested alternative, received ceftriaxone–sulbactam–disodium EDTA plus intravenous colistin, which, to our knowledge, represents the first reported neonatal use of this combinations. Cultures were sterilized by day 7; both survived with normal
Naini Puri +5 more
wiley +1 more source
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley +1 more source
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich +5 more
doaj +1 more source
Abstract There are currently no oral treatment options for infections caused by extended spectrum β‑lactamase‐producing Enterobacterales. Avibactam tomilopil, a novel oral prodrug of avibactam, is being developed in combination with the oral cephalosporin, ceftibuten, as a potential treatment for patients with complicated urinary tract infections ...
Siddhee A. Sahasrabudhe +13 more
wiley +1 more source
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List +8 more
doaj +1 more source
Development and application of PBPK modeling integrating CRRT as a virtual organ to characterize antimicrobial pharmacokinetics and optimize dosing in septic patients. ABSTRACT Continuous renal replacement therapy (CRRT) extracorporeal drug removal, sepsis‐related pathophysiological alterations, and reduced pathogen susceptibility to antimicrobials can
Yuanming Xing +7 more
wiley +1 more source

